Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 7, 2013; 19(5): 721-726
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721
Table 3 Complete virological suppression based on age and HBeAg status
| Age-log rank 0.001 (median) | ||
| < 40 yr- | 40-55 yr- | > 55 yr- |
| 12 mo (9.25-14.75) | 6 mo (5.01-6.99) | 6 mo (5.24-6.76) |
| Hepatitis B e antigen negative status-log rank 0.19 (median) | ||
| < 40 yr- | 40-55 yr- | > 55 yr- |
| 6 mo (4.05-7.95) | 6 mo (4.99-7.02) | 6 mo (5.59-6.41) |
| Hepatitis B e antigen positive status-log rank 0.19 (median) | ||
| < 40 yr- | 40-55 yr- | > 55 yr- |
| 18 mo (7.37-28.63) | 18 mo (14.17-26.47) | 6 mo (6.5-17.5) |
| Hepatitis B e antigen seroconversion rate based on age-log rank 0.559 (median) | ||
| < 40 yr- | 40-55 yr- | > 55 yr- |
| 36 mo (20.55-51.45) | 30 mo (18.46-41.54) | 6 mo (9.8-32.2) |
- Citation: Fahrtash-Bahin F, Kariyawasam VC, Gray T, Byth K, George J, Douglas MW. Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World J Gastroenterol 2013; 19(5): 721-726
- URL: https://www.wjgnet.com/1007-9327/full/v19/i5/721.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i5.721